{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:30:06Z","timestamp":1790623806815,"version":"4.1.0"},"reference-count":24,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Therapy using lutetium-177 dotatate (177LU) was approved in Europe for the treatment of advanced neuroendocrine tumors (NETs) in 2017. Since then, it has become part of the strategies in the treatment of NETs, making it now possible to evaluate real-life results. Research Design and Methods: Single-arm, retrospective, multicenter, cohort study of all the patients with metastatic NETs treated with 177LU (four cycles of 200 mCi every 8 weeks) in the two medical centers dedicated to the treatment of NETs from the region of Arag\u00f3n, Spain, from 2017 to 2024. Descriptive analysis of demographic characteristics, efficacy, and survival analysis were performed using the statistics software Jamovi 2.6.14. Results: Sixty-eight patients were included. The majority were male, and the most frequent primary location was the pancreas. The ORR was 30.9%. The DCR was 88%. The median OS was 47.4 months [95% CI, 25.6\u2013NE]. The median PFS was 26.1 months [95% CI, 18.5\u201368.3]. High-grade tumors, multiple previous treatments, and pancreatic location presented worse OS. In total, 42.6% presented any grade adverse event (17.2% hematologic, 30.9% GI symptoms). Conclusions: The efficacy of 177LU in our study is like that observed in similar studies. Acceptable tolerance has been shown. Pancreatic tumors, previous treatments, and higher grades demonstrated worse outcomes. The new research line must consider the use of treatment with 177LU in earlier lines for metastatic disease as well as its possible use in local or locally advanced disease.<\/jats:p>","DOI":"10.3390\/jcm14072384","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T03:25:02Z","timestamp":1743391502000},"page":"2384","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of the Real-Life Efficacy and Safety of the Treatment with Lutetium-177 Dotatate for Metastatic Neuroendocrine Tumors"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-5966-6792","authenticated-orcid":false,"given":"Sara Elena","family":"Campos Ram\u00edrez","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3501-0121","authenticated-orcid":false,"given":"Alejandro","family":"Andr\u00e9s Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Hospital Cl\u00ednico Universitario Lozano Blesa, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Blanco Abad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Gomila Pons","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6856-7013","authenticated-orcid":false,"given":"Pablo","family":"G\u00f3mez Mugarza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda Elena","family":"Ruffini Egea","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Gallart Caballero","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Polo Marques","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-0168","authenticated-orcid":false,"given":"Vicente","family":"Alonso Ordu\u00f1a","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1159\/000503721","article-title":"Neuroendocrine Neoplasms of the Small Bowel and Pancreas","volume":"110","author":"Clift","year":"2020","journal-title":"Neuroendocrinology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3322\/caac.21493","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","unstructured":"WHO Classification of Tumours Editorial Board (2019). Digestive System Tumours. WHO Classification of Tumours, IARC Press. [5th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13249","DOI":"10.1111\/jne.13249","article-title":"European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1007\/s11605-015-2931-z","article-title":"Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors","volume":"19","author":"Grandhi","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_7","first-page":"e3986","article-title":"Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review","volume":"11","author":"Maqsood","year":"2019","journal-title":"Cureus"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/ERC-20-0360","article-title":"Somatostatin receptor radionuclide therapy in neuroendocrine tumors","volume":"28","author":"Haider","year":"2021","journal-title":"Endocr.-Relat. Cancer."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2967\/jnumed.111.087932","article-title":"Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate","volume":"52","author":"Khan","year":"2011","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1080\/17474124.2019.1685381","article-title":"177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors","volume":"13","author":"Das","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00535-012-0642-8","article-title":"Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): Recent insights and advances","volume":"47","author":"Ito","year":"2012","journal-title":"J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","article-title":"[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): An open-label, randomised, phase 3 study","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.118.215848","article-title":"Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients","volume":"60","author":"Zhang","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.2967\/jnumed.120.258897","article-title":"Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE","volume":"62","author":"Strosberg","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Urso, L., Panareo, S., Castello, A., Ambrosio, M.R., Zatelli, M.C., Caracciolo, M., Tonini, E., Valpiani, G., Boschi, A., and Uccelli, L. (2022). Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu\/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14102009"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102141","DOI":"10.1016\/j.ctrv.2020.102141","article-title":"Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis","volume":"93","author":"Strosberg","year":"2021","journal-title":"Cancer Treat Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.124.268617","article-title":"177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1\/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial","volume":"66","author":"Satapathy","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13550-015-0142-y","article-title":"Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies","volume":"5","author":"Bison","year":"2015","journal-title":"EJNMMI Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","article-title":"Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant 177Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors","volume":"62","author":"Parghane","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"znae178","DOI":"10.1093\/bjs\/znae178","article-title":"Neoadjuvant 177Lu-DOTATATE for non-functioning pancreatic neuroendocrine tumours (NEOLUPANET): Multicentre phase II study","volume":"111","author":"Partelli","year":"2024","journal-title":"Br. J. Surg."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2384\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:06:09Z","timestamp":1760029569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/7\/2384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":24,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14072384"],"URL":"https:\/\/doi.org\/10.3390\/jcm14072384","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}